Overview

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2027-03-11

Target enrollment:

Participant gender:

Summary

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with isatuximab, and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).

Phase:

PHASE1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

belantamab mafodotin
isatuximab